Cellics Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Cellics Therapeutics's estimated annual revenue is currently $3.3M per year.(i)
  • Cellics Therapeutics's estimated revenue per employee is $104,000

Employee Data

  • Cellics Therapeutics has 32 Employees.(i)
  • Cellics Therapeutics grew their employee count by 10% last year.

Cellics Therapeutics's People

NameTitleEmail/Phone
1
VP, Head CMC and Regulatory AffairsReveal Email/Phone
2
Director, Downstream Process DevelopmentReveal Email/Phone
3
Associate Director Quality and Program ManagementReveal Email/Phone
4
President & CEO at Cellics TherapeuticsReveal Email/Phone
5
Senior ScientistReveal Email/Phone
6
Research Associate II — Process Development and ManufacturingReveal Email/Phone
7
Scientist, Analytical DevelopmentReveal Email/Phone
8
President and CEOReveal Email/Phone
9
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1770.7M952516%$2.3BN/A
#2
$21.6M151-3%N/AN/A
#3
$5.2M5014%N/AN/A
#4
$5920M62920%$552.3MN/A
#5
$1M13-41%N/AN/A
#6
$6.4M558%N/AN/A
#7
$1.6M25-44%$44MN/A
#8
$1.4M210%$4.7MN/A
#9
$2.5M28-10%N/AN/A
#10
$3.5M34-6%N/AN/A
Add Company

What Is Cellics Therapeutics?

Cellics Therapeutics, Inc. is a biotech company using the innovative Cellular Nanosponge platform technology to create treatment and vaccines for hard-to-treat infectious and inflammatory diseases. Cellics has a rich pipeline and has obtained significant proof of concept data in many different indications. Its leading indication is ready to move into clinical stage. Cellics team is currently expanding quickly and we are looking for innovative and goal-driven team members to join the team.

keywords:N/A

N/A

Total Funding

32

Number of Employees

$3.3M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.9M32N/AN/A
#2
$6.4M32-14%N/A
#3
$5M32-59%$3.4M
#4
$3.7M327%N/A
#5
$5.8M327%N/A